Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more
Samjin Pharm (005500) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.005x
Based on the latest financial reports, Samjin Pharm (005500) has a cash flow conversion efficiency ratio of -0.005x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.43 Billion) by net assets (₩264.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samjin Pharm - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Samjin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Samjin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samjin Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unichem Laboratories Limited
NSE:UNICHEMLAB
|
0.041x |
|
Union Medical Healthcare Limited
PINK:UNHLF
|
0.157x |
|
LX Hausys Ltd Preferred
KO:108675
|
0.096x |
|
Exotic Food Public Company Limited
BK:XO
|
0.107x |
|
Ihlas Holding AS
IS:IHLAS
|
-0.030x |
|
Centaurus Metals Limited
OTCQX:CTTZF
|
-0.280x |
|
Ador Welding Limited
NSE:ADORWELD
|
0.013x |
|
JUKCF
PINK:JUKCF
|
N/A |
Annual Cash Flow Conversion Efficiency for Samjin Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Samjin Pharm from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩261.66 Billion | ₩38.15 Billion | 0.146x | +364.31% |
| 2023-12-31 | ₩265.36 Billion | ₩8.33 Billion | 0.031x | -49.90% |
| 2022-12-31 | ₩275.86 Billion | ₩17.29 Billion | 0.063x | -38.75% |
| 2021-12-31 | ₩234.17 Billion | ₩23.97 Billion | 0.102x | -8.44% |
| 2020-12-31 | ₩213.46 Billion | ₩23.86 Billion | 0.112x | -6.60% |
| 2019-12-31 | ₩197.47 Billion | ₩23.63 Billion | 0.120x | -18.32% |
| 2018-12-31 | ₩205.32 Billion | ₩30.08 Billion | 0.147x | -23.97% |
| 2017-12-31 | ₩193.47 Billion | ₩37.28 Billion | 0.193x | -32.79% |
| 2016-12-31 | ₩169.69 Billion | ₩48.66 Billion | 0.287x | +124.21% |
| 2015-12-31 | ₩148.06 Billion | ₩18.94 Billion | 0.128x | -50.26% |
| 2014-12-31 | ₩126.04 Billion | ₩32.41 Billion | 0.257x | +293.92% |
| 2013-12-31 | ₩112.98 Billion | ₩7.37 Billion | 0.065x | -- |